Jabbour E, Sasaki K, Haddad FG, Issa GC, et al. Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol 2022 Aug 13. doi: 10.1002/ajh.26689.
PMID: 36054032